« Home « Kết quả tìm kiếm

Circulating tumor cells

Tìm thấy 10+ kết quả cho từ khóa "Circulating tumor cells"

TRAIL-coated leukocytes to kill circulating tumor cells in the flowing blood from prostate cancer patients

tailieu.vn

Circulating tumor cells and stromal cell mobilization due to primary tumor resection lends support to the idea that adjuvant therapy to reduce CTC clusters or CTC or CAF levels in the blood- stream, may prevent or delay cancer recurrence and metastasis.

Novel microfluidic approaches to circulating tumor cell separation and sorting of blood cells: A review

tailieu.vn

Han, Microfluidic technol- ogies for circulating tumor cell isolation, Analyst e2970.. Jiang, Microfluidics-based approaches for separation and analysis of circulating tumor cells, Trac. Cui, Sorting technology for circulating tumor cells based on microfluidics, ACS Comb. Xiang, Recent advances in microfluidic cell sorting techniques based on both physical and biochemical principles, Electrophoresis e954..

Cell-free DNA and circulating tumor cell kinetics in a pre-clinical head and neck Cancer model undergoing radiation therapy

tailieu.vn

The prognostic significance of circulating tumor cells in head and neck and non-small-cell lung cancer. https://doi.org/10.1002/cam4.1832.. The isolation and characterization of circulating tumor cells from head and neck Cancer patient blood samples using spiral microfluidic technology. https://doi.org . Cancer of the oral cavity. https://doi.org/10.1016/j.soc .

Removal of EpCAM-positive tumor cells from blood collected during major oncological surgery using the Catuvab device-a pilot study

tailieu.vn

The spreading of tumor cells during surgery can originate from tumor cells left at the resection line, inadvertent rupture of the tumor, prior presence of tumor cells in the peritoneal cavity, or intraoperative release into the blood by pressurization, but unlikely from circulating tumor cells [28, 29].

Circulating activated immune cells as a potential blood biomarkers of non-small cell lung cancer occurrence and progression

tailieu.vn

Increased CD8+CD28+ T cells independently predict better early response to stereotactic ablative radiotherapy in patients with lung metastases from non-small cell lung cancer. Circulating tumor cells were associated with the number of T lymphocyte subsets and NK cells. in peripheral blood in advanced non-small-cell lung cancer. Predictive value of peripheral regulatory T cells in non-small cell lung cancer patients under- going radiotherapy.

Predictors of breast cancer cell types and their prognostic power in breast cancer patients

tailieu.vn

Prognostic potential of 6 sets of cell specific predictors in TCGA breast cancer patients, Cells belonging to the same type cluster together. Clonal evolution in breast cancer revealed by single nucleus genome sequencing. Circulating tumor cell clusters are oligoclonal precursors of breast cancer metastasis. Single cell profiling of circulating tumor cells: transcriptional heterogeneity and diversity from breast cancer cell lines.

Epidural anesthesia and cancer outcomes in bladder cancer patients: Is it the technique or the medication? A matched-cohort analysis from a tertiary referral center

tailieu.vn

Significant detection of circulating cancer cells in the blood by reverse transcriptase-polymerase chain reaction during colorectal cancer resection. Wang JY, Wu CH, Lu CY, et al. Molecular detection of circulating tumor cells in the peripheral blood of patients with colorectal cancer using RT-PCR:. significance of the prediction of postoperative metastasis.

Characterization of surface markers on extracellular vesicles isolated from lymphatic exudate from patients with breast cancer

tailieu.vn

Furthermore, breast cancer cells as well as circulating tumor cells are of epithelial origin, and thus CD45 negative [50], it is thus possible that the EVs originate from those cells. EpCAM, as well as the cancer-related protein CD24, has been detected on EVs isolated from ascites and pleural effusions from breast cancer patients. Other cancer-related markers that were detected on the surface of the EVs from all patients were CD29, CD44 and CD146.

Applied electric field analysis and numerical investigations of the continuous cell separation in a dielectrophoresis-based microfluidic channel

tailieu.vn

A simulation model was also used to explore the performance of the design in the isolation of circulating tumor cells (CTCs).. It revealed that the optimal conditions of the device are suitable to effectively separate CTCs from red blood cells (RBCs) within the channel structure, with a high flow rate of 1.5 m L/min, and an electric amplitude as low as 10 V pp , at the frequency of 1 kHz.

Comprehensive analysis of coagulation indices for predicting survival in patients with biliary tract cancer

tailieu.vn

Fibrinogen is an important determinant of the metastatic potential of circulating tumor cells. https://doi.org/10.1182/. https://doi.org . https://doi.org/1 0.1097/IGC . https://doi.org/10.1097/MPA . https://doi.org/10.1 016/j.suronc . https://doi.org/10.1111/. https://doi.org/10.. https://doi.org/10.6004/jnccn.2019.7357.

Integration of circulating tumor cell and neutrophil-lymphocyte ratio to identify high-risk metastatic castration-resistant prostate cancer patients

tailieu.vn

Circulating tumor cells in patients with castration-resistant prostate cancer baseline values and correlation with prognostic factors. https://doi.org EPI-08-1173.. Circulating tumor cell biomarker panel as an individual-level surrogate for survival in metastatic castration-resistant prostate cancer.

The role of FoxP3+ regulatory T cells and IDO+ immune and tumor cells in malignant melanoma – an immunohistochemical study

tailieu.vn

IDO expression in tumor cells is more abundant in malignant melanoma, compared with benign lesions The coverage and intensity of IDO+ tumor cells was also analysed. The number of IDO+ tumor cells was low, but they most often localized in the invasive front in the same area as the IDO+ stromal immune cells (Fig. The staining pattern of IDO+. tumor cells was also cytoplasmic. The coverage of IDO+.

A high CD8 to FOXP3 ratio in the tumor stroma and expression of PTEN in tumor cells are associated with improved survival in non-metastatic triple-negative breast carcinoma

tailieu.vn

The description of the frequency of these cells in the intratumoral or stromal compartments is very heteroge- neous in the literature, as well as the determination of its clinical significance [21]. evaluated in the tumor cells or in the tumor stroma. PD-L1 Tumor 62 4.53. PD-L1 Estroma 48 12.17. Table 3 Association between clinical-pathological characteristics and the expression of PD-1, PD-L1 in tumor cells and in stromal cells.

Neoadjuvant everolimus plus letrozole versus fluorouracil, epirubicin and cyclophosphamide for ER-positive, HER2- negative breast cancer: A randomized pilot trial

tailieu.vn

Changes of circulating tumor- specific CTLs after neoadjuvant endocrine therapy (NET). Changes of circulating tumor-specific CTLs after neoadjuvant chemotherapy (NAC).. Neoadjuvant therapy-induced changes of tumor biomarkers. Baseline proportions of Ki67-positive tumor cells in tumor samples in the neoadjuvant endocrine therapy (NET) and neoadju- vant chemotherapy (NAC) group.

Circulating MiR-1290 as a potential diagnostic and disease monitoring biomarker of human gastrointestinal tumors

tailieu.vn

Human gastrointestinal tumor cells express and secrete miR-1290. We examined the expression of miR-1290 in human gastrointestinal tumor cell lines to clarify the source of circulating miR-1290. The expression level of miR- 1290 was lower in GC cell lines than in CRC and PC cell lines. 3b-f, gastrointestinal tumor cells expressed and secreted miR-1290 into the culture. supernatant, and the miR-1290 expression level in the culture supernatant increased with both cell density and culture time.

Restricting tumor lactic acid metabolism using dichloroacetate improves T cell functions

tailieu.vn

A promising therapeutic strategy is to target the glyco- lysis pathway of tumor cells as the impairment of glucose metabolism could cause defects in tumor cells growth and survival [36, 37] It further decreases their lactic acid secretion and acidification of the tumor microen- vironment that impairs the T and NK cells’ anti-tumor immune responses .

Association of emergence of new mutations in circulating tumuor DNA during chemotherapy with clinical outcome in metastatic colorectal cancer

tailieu.vn

Clinical validation of the detection of KRAS and BRAF mutations from circulating tumor DNA. https://doi.org/10.1038/nm.3511.. doi.org . https://doi.org/10.1038/ncomms9760.. Shitara K, Yamanaka T, Denda T, Tsuji Y, Shinozaki K, Komatsu Y, et al. https://doi.org/10.1093/a nnonc/mdy526.

Histone deacetylase inhibitor panobinostat induces antitumor activity in epithelioid sarcoma and rhabdoid tumor by growth factor receptor modulation

tailieu.vn

Panobi- nostat strongly reduced ERK phosphorylation in A204, VAESBJ and GRU1 cells, which was durable in epithelioid sarcoma cells (Fig. Rhabdoid tumor cells exhibit sensitivity towards multi- tyrosine kinase inhibition whereas oncogenic signaling is activated in epithelioid sarcoma. 2B), both epithelioid sarcoma cell lines were not sensitive to erlotinib.

Chapter 065. Gene Therapy in Clinical Medicine (Part 3)

tailieu.vn

Some of the earliest cancer gene therapy trials focused on local delivery of a prodrug or a suicide gene that would increase sensitivity of tumor cells to cytotoxic drugs. A frequently used strategy has been intratumoral injection of an adenoviral vector expressing the thymidine kinase (TK) gene. Cells that take up and express the TK gene can be killed after the administration of gancyclovir, which is phosphorylated to a toxic nucleoside by TK.

Identification and characterization of genes with absolute mRNA abundances changes in tumor cells with varied transcriptome sizes

tailieu.vn

More than 96% REOs in the tumor tissues with above 70% of proportion of epithelial cells are consistent with the REOs in tumor epithelial cells, and about 90% REOs in tumor epithelial cells are kept in tumor tissues even when the proportion of epithelial cells decreases to 30% [41].